Takashige Okayama

Statistics

Publications

Citations

231

H-Index

Active since

2004

Affiliations

Taiho Pharmaceutical (Japan)(Current)

Hiroshima International University

Hiroshima University

Takashige Okayama is an author at Taiho Pharmaceutical (Japan) specializing in pharmacology, medicine, and oncogenic receptor tyrosine kinase mutations.

Publications per year

2004–2021

Publications

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Shinichi Hasako, Miki Terasaka, Naomi Abe et al. · Molecular Cancer Therapeutics · 2018 · 85 citations

Medicine, Oncology, Pharmacology +17

Aryl hydrocarbon receptor-mediated induction of microsomal drug-metabolizing enzyme activity by indirubin and indigo

Kazumi Sugihara, Shigeyuki Kitamura, Tsuyoshi Yamada et al. · Biochemical and Biophysical Research Communications · 2004 · 78 citations

Medicine, Biochemistry, Pharmacology +14

Comparative study of aryl hydrocarbon receptor ligand activities of six chemicals in vitro and in vivo

Kazumi Sugihara, Takashige Okayama, Shigeyuki Kitamura et al. · Archives of Toxicology · 2007 · 34 citations

Medicine, Chemistry, Pharmacology +11

Analytical Method Validation for Biomarkers As a Drug Development Tool: Points to Consider

Yoshiaki Ohtsu, Seiji Tanaka, Harue Igarashi et al. · Bioanalysis · 2021 · 21 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +17

TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various <i>EGFR</i> Mutations Including T790M and Uncommon Mutations G719X

Kimihiro Ito, Makoto Nishio, Masanori Kato et al. · Molecular Cancer Therapeutics · 2019 · 13 citations

Medicine, Oncology, Pharmacology +16

1–5 of 5